Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Sintilimab in advanced MSS colorectal cancer
NCT04764006Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in colorectal cancer (CRC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
surufatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04764006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764006.